Maximum Dose for Ozempic for Weight Control
The maximum dose of Ozempic (semaglutide) for weight control is 1 mg once weekly, as this is the FDA-approved maximum dose for this specific formulation 1. However, it's critical to understand that Ozempic is NOT FDA-approved for weight management—it is only approved for type 2 diabetes and cardiovascular risk reduction in diabetic patients 1.
Critical Distinction: Ozempic vs. Wegovy
For weight management specifically, you should be prescribing Wegovy (semaglutide 2.4 mg), not Ozempic. While both contain semaglutide, they are different products with different approved indications and maximum doses:
- Ozempic: Maximum 1 mg weekly, approved only for type 2 diabetes 1
- Wegovy: Maximum 2.4 mg weekly, FDA-approved specifically for weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidities 2
Dosing Algorithm for Weight Management
If prescribing semaglutide specifically for weight control, the proper approach is:
Standard Wegovy Dosing (2.4 mg formulation):
- Week 1-4: 0.25 mg once weekly (initiation dose, not therapeutic)
- Week 5-8: 0.5 mg once weekly
- Week 9-12: 1.0 mg once weekly
- Week 13-16: 1.7 mg once weekly
- Week 17+: 2.4 mg once weekly (maintenance dose) 3
Emerging Higher Dose Option:
Recent evidence shows semaglutide 7.2 mg once weekly achieved superior weight loss compared to 2.4 mg (-18.7% vs -15.6% body weight at 72 weeks) with acceptable safety, though this is not yet FDA-approved 4.
Expected Outcomes with Proper Dosing
With the FDA-approved 2.4 mg dose for weight management:
- Mean weight loss: 14.9-16.0% at 68 weeks in patients without diabetes 2
- Cardiovascular benefit: 20% reduction in major adverse cardiovascular events (HR 0.80,95% CI 0.72-0.90) in patients with established CVD 2
- Real-world effectiveness: 14.1% weight loss at 1 year with persistent use 5
Common Pitfall to Avoid
Do not use Ozempic off-label for weight management when Wegovy is available. The 1 mg maximum dose of Ozempic provides suboptimal weight loss compared to the 2.4 mg Wegovy dose. The STEP trials clearly demonstrated dose-dependent efficacy, with higher doses producing significantly greater weight reduction 2, 3.
Safety Considerations
Contraindications (apply to all semaglutide formulations):
- Personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- History of pancreatitis (relative contraindication) 3, 1
Most common adverse effects: Gastrointestinal symptoms (nausea, vomiting, diarrhea) occur in 60-70% of patients, managed through gradual dose escalation 3
Long-Term Use Required
Semaglutide must be continued indefinitely for sustained weight loss. Discontinuation results in significant weight regain—patients regained 11.6% of lost weight within 52 weeks after stopping treatment 2. This medication requires lifelong use in conjunction with lifestyle modifications for maintained efficacy.